CELL INTELLIGENCE · 肿瘤细胞治疗研究

复发性/难治性多发性骨髓瘤伴髓外浆细胞瘤在疾病晚期成功再挑战人源化 B 细胞成熟抗原靶向 CAR-T 细胞免疫治疗：一例病例报告

Relapsed/refractory multiple myeloma with extramedullary plasmacytomas successfully rechallenged with humanized B-cell maturation antigen-directed chi

将 B 细胞与浆细胞靶向从肿瘤学转化至自身免疫：模式、定量桥接与开发路线图

Translating B-Cell and Plasma-Cell Targeting from Oncology to Autoimmunity: Modalities, Quantitative Bridging, and a Development Roadmap.

CD38 靶向 CAR-T 细胞治疗多发性骨髓瘤的疗效与安全性：系统综述与荟萃分析

Efficacy and safety of CD38-directed CAR-T cell therapy for multiple myeloma: a systematic review and meta-analysis.

双靶点 CD38/BCMA CAR-T 在 RRMM 中显示出有前景的疗效和可控的安全性。

靶向 GPRC5D 的 CAR-T 细胞治疗复发/难治性多发性骨髓瘤：病例报告与文献综述

Targeting GPRC5D With CAR-T Cells in Relapse/Refractory Multiple Myeloma: Case Report and Literature Review.

靶向 Wnt/β-catenin 信号通路增强抗 CD38 免疫治疗在多发性骨髓瘤中的疗效

Targeting Wnt/β-catenin signaling enhances the efficacy of anti-CD38 immunotherapy in multiple myeloma.

这些发现表明，靶向 Wnt 信号通路可增强 daratumumab 的疗效，并为将 daratumumab 与 Wnt 信号通路抑制联合作为 MM 的治疗策略提供了强有力的依据。

矢车菊素-3-O-葡萄糖苷介导的调节性 T 细胞减少：多发性骨髓瘤的治疗策略

Cyanidin-3-O-glucoside-mediated reduction of regulatory T cells: a therapeutic strategy for multiple myeloma.

C3G 通过减少 Tregs 比例从而恢复抗肿瘤免疫，对 MM 发挥治疗作用。其机制可能与抑制 CD38 介导的 GZMB 水平降低有关。

多发性骨髓瘤细胞中 ALDH1A1 表达降低通过下调视黄酸增加对 daratumumab 的耐药性

Reduced ALDH1A1 expression in multiple myeloma cells increases resistance to daratumumab via downregulation of retinoic acid.

多发性骨髓瘤中的 T 细胞功能障碍

T Cells Dysfunction in Multiple Myeloma.

复发/难治性多发性骨髓瘤临床实践中基于抗 CD38 治疗的共识指南与推荐：来自泛太平洋多发性骨髓瘤工作组

Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-P

骨髓免疫生态系统塑造了浆细胞骨髓瘤中达雷妥尤单抗的获得性耐药

The bone marrow immune ecosystem shapes daratumumab acquired resistance in plasma cell myeloma.